Atomo Diagnostics Limited
AT1.ASXHealth Care
The expansion of global sales and continued development of its rapid test device technologies.
Market Data
$0.020
+0.0%$17.6M
-100000.0x
$-0.006
0.00%
-0.4%
Latest Earnings
Appendix 4D and Half Year Report ended 31 Dec 2025
26 February 2026
Atomo Diagnostics reported a 38% improvement in its net loss to $1.65M for HY26, down from $2.75M in the prior period, while revenue grew 6% to $2.18M. The company successfully reduced operating expenses by approximately $700k (35% reduction in resource costs) and maintained cash reserves of $3.5M following a capital raise during the period. Key points: Net loss narrowed 38% to $1.65M, representing $1.1M improvement versus prior period; Revenue grew 6% to $2.18M with product sales of $1.04M for HIV tests and $988k for OEM technology; Operating expenses reduced by ~$700k (35% reduction in resource costs) demonstrating effective cost optimization
Recent Announcements
Appendix 4D and Half Year Report ended 31 Dec 2025
Atomo Diagnostics reported a 38% improvement in its net loss to $1.65M for HY26, down from $2.75M in the prior period, while revenue grew 6% to $2.18M. The company successfully reduced operating expenses by approximately $700k (35% reduction in resource costs) and maintained cash reserves of $3.5M following a capital raise during the period. Key points: Net loss narrowed 38% to $1.65M, representing $1.1M improvement versus prior period; Revenue grew 6% to $2.18M with product sales of $1.04M for HIV tests and $988k for OEM technology; Operating expenses reduced by ~$700k (35% reduction in resource costs) demonstrating effective cost optimization
Get real-time alerts for AT1
Receive AI-powered earnings summaries and instant notifications when Atomo Diagnostics Limited releases results.
Register Free